Evidence map›Paper›PMID 34141082›Full record

ArticleACS medicinal chemistry letters2021

Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.

Michael G Yang, Zili Xiao, Rulin Zhao, Andrew J Tebben, Bei Wang, Robert J Cherney, Douglas G Batt, Gregory D Brown, Mary Ellen Cvijic, John V Duncia and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Michael G YangResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.ORCID https://orcid.org/0000-0003-2908-4060
Zili XiaoResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Rulin ZhaoResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Andrew J TebbenResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Bei WangResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Robert J CherneyResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.ORCID https://orcid.org/0000-0002-6642-2834
Douglas G BattResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Gregory D BrownResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Mary Ellen CvijicResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
John V DunciaResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Michael A GallelaResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Daniel S GardnerResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Purnima KhandelwalResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Mary F MalleyResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Jian PangResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Anne V RoseResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Joseph B SantellaResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Amy A SarjeantResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Songmei XuResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Arvind MathurResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Sandhya MandlekarResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Ragini VuppugallaResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Qihong ZhaoResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Percy H CarterResearch and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
Bristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To improve the metabolic stability profile of BMS-741672 (

Identifiers

PMID34141082
PMCPMC8201760
OpenAlexW3165585314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.